CRDL
Cardiol Therapeutics Inc - Ordinary Shares - Class A

5,569
Mkt Cap
$138.99M
Volume
612,638.00
52W High
$2.24
52W Low
$0.7709
PE Ratio
-3.42
CRDL Fundamentals
Price
$1.22
Prev Close
$1.19
Open
$1.17
50D MA
$1.10
Beta
1.24
Avg. Volume
806,841.95
EPS (Annual)
-$0.3741
P/B
11.37
Rev/Employee
$0.00
Loading...
Loading...
News
all
press releases
Zacks Industry Outlook Highlights Akebia Therapeutics, Ironwood Pharmaceuticals, Pyxis Oncology, Cardiol Therapeutics and Plus Therapeutics
Small-cap biotech momentum surges as AKBA, IRWD, PYXS, CRDL, and PSTV gain on pipeline progress and sector recovery.
Zacks·12d ago
News Placeholder
More News
News Placeholder
5 Small Drug Stocks to Buy as the Industry Shows Some Recovery
Innovation is at its peak in the Zacks Medical-Drugs industry. AKBA, IRWD, PYXS, CRDL and PSTV may prove to be good additions to one's portfolio.
Zacks·13d ago
News Placeholder
Why Cardiol Therapeutics (CRDL) Stock Is Down 20% Today
Cardiol Therapeutics shares are trading lower by 20% Wednesday morning. The company announced a $13.5 million public offering. read more...
Benzinga·1y ago
News Placeholder
Cardiol Therapeutics Gains Key Legal Consent
Cardiol Therapeutics (TSE:CRDL) has released an update. Cardiol Therapeutics Inc. has received consent from Borden Ladner Gervais LLP for the use o...
TipRanks Financial Blog·1y ago
News Placeholder
Analysts Offer Insights on Healthcare Companies: Cardiol Therapeutics (CRDL), Paragon 28 (FNA) and Intra-Cellular Therapies (ITCI)
There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Cardiol Therapeutics (CRDL Research Report), Paragon 28...
TipRanks Financial Blog·2y ago
News Placeholder
CRDL Stock Earnings: Cardiol Therapeutics Beats EPS for Q4 2023
InvestorPlace - Stock Market News, Stock Advice & Trading Tips CRDL stock results show that Cardiol Therapeutics beat analyst estimates for earnings per share the fourth quarter of 2023. The post...
InvestorPlace·2y ago
News Placeholder
Cardiol Therapeutics Progresses in Heart Disease Trials
Cardiol Therapeutics Inc. (TSE:CRDL) has released an update. Cardiol Therapeutics Inc. has made significant strides by completing patient enrollmen...
TipRanks Financial Blog·2y ago
News Placeholder
Cardiol Therapeutics Announces Year-End 2023 Update on Operations
Completed patient enrollment in the Phase II MAvERIC-Pilot study evaluating CardiolRx in patients withrecurrent pericarditis, with topline results expected in Q2 2024CardiolRx granted...
Newsfile Corp. - News Releases·2y ago
News Placeholder
Cardiol Therapeutics Inc at Cantor Fitzgerald Global Healthcare Conference Transcript
Related Stocks: TSX:CRDL...
GuruFocus·2y ago
News Placeholder
Cardiol Therapeutics Inc at Emerging Growth Conference Transcript
Related Stocks: TSX:CRDL...
GuruFocus·2y ago

Latest CRDL News

View

Advertisement|Remove ads.

Advertisement|Remove ads.